MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Stock Chart & Stats
$18.02
-$0.83(-1.65%)
At close: 4:00 PM EST
$18.02
-$0.83(-1.65%)
Day’s Range― - ―
52-Week Range$5.95 - $62.75
Previous CloseN/A
Volume45.38K
Average Volume (3M)1.08M
Market Cap
$1.27B
Enterprise Value$1.01B
Total Cash (Recent Filing)$393.97M
Total Debt (Recent Filing)$75.71M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
May 07, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding71,727,875
10 Day Avg. Volume744,034
30 Day Avg. Volume1,075,544
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-4.33
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-453.24
Enterprise Value/Ebitda-4.61
Forecast
1Y Price Target
$28.57Price Target Upside58.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-3.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Across IndicationsConsistent clinical signals, including symptomatic improvement and MRI-confirmed reductions in inflammation in axial spondyloarthritis, support the drug's potential to demonstrate meaningful benefit across dermatology and rheumatology indications.
Financial RunwayA strong cash position combined with access to non-dilutive financing supports continued development and the ability to pursue additional indications without immediate equity dilution.
Regulatory PathwayRegulatory feedback and an agreement with the FDA permit submission of a marketing application for the hidradenitis suppurativa program, creating a clear route toward potential approval and commercialization.
Bears Say
Funding And Analyst SentimentDependence on upcoming clinical milestones for funding and a sell rating from a covering analyst increase downside risk if trials or lender approvals do not progress as expected.
Placebo Response RiskAn increased placebo response in a pivotal trial complicated efficacy interpretation and underscores the risk that future studies may fail to meet primary endpoints.
Trial Outcome UncertaintyMixed late-stage results and a narrowly missed primary endpoint in one hidradenitis suppurativa study raise uncertainty about whether the overall dataset will satisfy regulators and drive approval.
MoonLake Immunotherapeutics News
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $5.95 and its highest was $62.75 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $1.27B.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is May 07, 2026 which is in 41 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Feb 22, 2026. The company reported -$0.931 earnings per share for the quarter, beating the consensus estimate of -$0.964 by $0.033.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.9.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 71,727,875 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.931 in its last earnings report, beating expectations of -$0.964. Following the earnings report the stock price went up 4.541%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MoonLake Immunotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.57 (58.55% Upside)
$28.57 (58.55% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 12.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.57%
12-Months-Change
Fundamentals
Return on Equity
-67.12%
Trailing 12-Months
Asset Growth
-11.19%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MLTX Stock 12 Month Forecast
Average Price Target
$28.57
▲(58.55% Upside)
Technical Analysis
Protagonist Therapeutics
―
Zai Lab
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
―
Ownership Overview
36.40% Insiders
2.29% Mutual Funds
51.75% Other Institutional Investors
8.95% Public Companies and Individual Investors